Physician profile
Connor C Chase
NPI 1225066616
$1,306.27
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $606 · 2021: $224.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $275.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.46 | 2019-2021 | |
| Glaxosmithkline, LLC. | $106.89 | 2019-2021 | |
| Amgen INC. | $102.39 | 2019-2020 | |
| Amarin Pharma, INC. | $98.63 | 2019-2021 | |
| Novo Nordisk INC | $95.57 | 2019-2021 | |
| Pfizer INC. | $93.45 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $58.65 | 2019-2021 | |
| Abbvie INC. | $43.72 | 2019-2021 | |
| Lilly USA, LLC | $38.93 | 2020-2021 | |
| Allergan, INC. | $36.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $23.63 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $21.26 | 2020 | |
| Corcept Therapeutics | $20.71 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $20.07 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.42 | 2019 | |
| Astellas Pharma US INC | $17.28 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $15.72 | 2020 | |
| Merck Sharp & Dohme LLC | $11.54 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.